ArticleScience advances2025

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.

Margaux Saillard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.